公开(公告)号：US20190256483A1

公开(公告)日：2019-08-22

申请号：US16318590

申请日：2017-07-24

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Martin K. SAFO ,  Guoyan XU ,  Yan ZHANG ,  Osheiza ABDULMALIK

IPC: C07D307/46 ,  C07F9/655 ,  A61P7/00 ,  A61P43/00

Abstract: Prodrugs and derivatives of 5-hydoxymethyl-2-furfural (5-HMF) with protected or modified aldehyde and/or alcohol moieties are provided. The prodrugs or derivatives exhibit increased bioavailability, e.g. due to having extended half-lives in circulation. The drugs are therefore administered i) at lower doses and/or ii) less frequently than 5-HMF, while still maintaining the beneficial therapeutic effects of 5-HMF.

公开(公告)号：US20220340531A1

公开(公告)日：2022-10-27

申请号：US17846101

申请日：2022-06-22

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY ,  THE CHILDREN'S HOSPITAL OF PHILADELPHIA

Inventor： Martin K. SAFO ,  Yan ZHANG ,  Piyusha Pradeep PAGARE ,  Guoyan XU ,  Mohini GHATGE ,  Jurgen VENITZ ,  Osheiza ABDULMALIK

IPC: C07D213/80 ,  A61P7/00 ,  A61K9/00 ,  C07D213/79 ,  C07D401/04 ,  C07D409/04

Abstract: Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are based on vanillin which is chemically modified to increase bioavailability and activity, e.g. so that the compounds bind to the F helix of hemoglobin (Hb) and prevent adhesion of red blood cells (RBCs).

公开(公告)号：US20210002225A1

公开(公告)日：2021-01-07

申请号：US16982745

申请日：2019-03-18

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY ,  THE CHILDREN'S HOSPITAL OF PHILADELPHIA

Inventor： Martin K. SAFO ,  Yan ZHANG ,  Piyusha Pradeep PARAGE ,  Guoyan XU ,  Mohini GHATGE ,  Jurgen VENITZ ,  Osheiza ABDULMALIK

IPC: C07D213/80 ,  C07D213/79 ,  C07D401/04 ,  C07D409/04 ,  A61K9/00 ,  A61P7/00

Abstract: Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are based on vanillin which is chemically modified to increase bioavailability and activity, e.g. so that the compounds bind to the F helix of hemoglobin (Hb) and prevent adhesion of red blood cells (RBCs).

公开(公告)号：US20160326097A1

公开(公告)日：2016-11-10

申请号：US15107962

申请日：2014-12-22

Applicant: VIRGINIA COMMONWEALTH UNIVERSITY

Inventor： Martin K. SAFO ,  Richmond DANSO-DANQUAH ,  Mohini GHATGE ,  Jurgen VENITZ ,  Martin MANGINO ,  Kevin R. WARD

IPC: C07C235/38 ,  A61K33/00 ,  A61K45/06 ,  A61K31/216 ,  C07C245/24 ,  A61K31/655

CPC classification number: C07C235/38 ,  A61K31/216 ,  A61K31/40 ,  A61K31/655 ,  A61K33/00 ,  A61K45/06 ,  C07C245/24 ,  Y02A50/411 ,  A61K2300/00

Abstract: Allosteric hemoglobin (Hb) modifiers of hemoglobin which contain nitric oxide (NO) moieties allowing for the release of NO in vivo. The compounds retain the oxygen delivery capability of the allosteric hemoglobin modifier to bind Hb and enhance Hb's ability to deliver oxygen to cells and tissues, and also release NO from the NO moiety. Methods of delivering oxygen and/or NO to cells and tissues are also provided.

Abstract translation: 含有一氧化氮（NO）部分的血红蛋白的变构血红蛋白（Hb）改性剂允许体内释放NO。 化合物保留变构血红蛋白改性剂的氧传递能力以结合Hb并增强Hb将氧递送至细胞和组织的能力，并且还从NO部分释放NO。 还提供了向细胞和组织输送氧和/或NO的方法。